{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:20:43Z","timestamp":1790223643697,"version":"4.1.0"},"reference-count":29,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background and Objectives: Ocrelizumab significantly reduces inflammatory activity in relapsing-remitting multiple sclerosis (RRMS), but treatment-induced brain volume change and the specific contributions of white matter (WM), gray matter (GM), and cerebrospinal fluid (CSF) compartments to global atrophy and pseudoatrophy remain unclear. We aim to characterize the longitudinal and infusion-related dynamics of brain compartments in ocrelizumab-treated RRMS patients and identify the clinical and time-dependent predictors of these changes. Methods: Fifty-one RRMS patients were enrolled in a four-year prospective study. Brain volumes, including WM, GM, peripheral GM (pGRAY), CSF, ventricular CSF (vCSF), total brain volume (TBV) and their respective fractions (WMF, GMF, BPF) were evaluated by absolute time points (baseline to 4 years) and infusion-based intervals (baseline to 8th infusion), before and after each ocrelizumab cycle. Correlations between brain volume measures and the Expanded Disability Status Scale (EDSS), as well as time-dependent variables such as age, age at onset and disease duration (DD) were examined. Results: Mean age was 41.62 \u00b1 9.76 years, mean age at onset 28.17 \u00b1 7.85, mean DD 12.89 \u00b1 8.55 years and mean EDSS 3.26 \u00b1 1.5, indicating moderate disability. During the study, vCSF and CSF significantly increased, whereas WM, WMF, TBV and BPF significantly decreased. Notably, these measures exhibited marked, non-linear, and transient changes during the first year of ocrelizumab treatment, consistent with pseudoatrophy, likely reflecting early resolution of inflammation rather than irreversible tissue loss. GM and pGRAY remained relatively stable, with minor early increases. Correlation analyses revealed that higher EDSS scores, older age, later age at onset and longer DD were associated with lower GM, pGRAY and TBV, emphasizing the interplay between disease progression and development of brain volumetric patterns. Conclusions: Ocrelizumab-induced pseudoatrophy is predominantly WM-driven and age-dependent, with WM shrinkage being the main contributor to parenchymal loss and secondary widening of CSF spaces. Age remains a powerful predictor of brain atrophy and neurological impairment. These findings provide mechanistic insights into the biological basis of this modulation in RRMS.<\/jats:p>","DOI":"10.3390\/ph19060827","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T15:05:08Z","timestamp":1779721508000},"page":"827","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ocrelizumab-Induced Brain Volume Dynamics in Relapsing-Remitting Multiple Sclerosis"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7587-8112","authenticated-orcid":false,"given":"Roberto","family":"De Masi","sequence":"first","affiliation":[{"name":"Laboratory of Neuroproteomics, Multiple Sclerosis Centre, \u201cF. Ferrari\u201d Hospital, 73042 Casarano, Lecce, Italy"},{"name":"Complex Operative Unit of Neurology, \u201cF. Ferrari\u201d Hospital, 73042 Casarano, Lecce, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2403-9228","authenticated-orcid":false,"given":"Stefania","family":"Orlando","sequence":"additional","affiliation":[{"name":"Laboratory of Neuroproteomics, Multiple Sclerosis Centre, \u201cF. Ferrari\u201d Hospital, 73042 Casarano, Lecce, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"ref_1","unstructured":"Multiple Sclerosis International Federation (MSIF) (2025, December 09). New Prevalence and Incidence Data Now Available in the Atlas of MS. Published 21 August 2023. Available online: https:\/\/www.msif.org\/news\/2023\/08\/21\/new-prevalence-and-incidence-data-now-available-in-the-atlas-of-ms\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple sclerosis","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMra052130","article-title":"Multiple sclerosis\u2014the plaque and its pathogenesis","volume":"354","author":"Frohman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","article-title":"Ocrelizumab in relapsing-remitting multiple sclerosis: A phase 2, randomised, placebo-controlled, multicentre trial","volume":"378","author":"Kappos","year":"2011","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/ana.24018","article-title":"Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis","volume":"75","author":"Sormani","year":"2014","journal-title":"Ann. Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1177\/13524585231162586","article-title":"Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging","volume":"29","author":"Kolind","year":"2023","journal-title":"Mult. Scler. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1177\/13524585221097561","article-title":"Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS","volume":"28","author":"Arnold","year":"2022","journal-title":"Mult. Scler. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"118233","DOI":"10.1016\/j.lfs.2020.118233","article-title":"IFI35 as a biomolecular marker of neuroinflammation and treatment response in multiple sclerosis","volume":"259","author":"Orlando","year":"2020","journal-title":"Life Sci."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"De Masi, R., and Orlando, S. (2021). GANAB as a Novel Biomarker in Multiple Sclerosis: Correlation with Neuroinflammation and IFI35. Pharmaceuticals, 14.","DOI":"10.3390\/ph14111195"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"De Masi, R., Orlando, S., Greco, A., and Costa, M.C. (2025). The Age-Related Efficacy of Dimethyl Fumarate in Naive Versus Switcher Multiple Sclerosis Patients: A Multicenter Population-Based Study. Pharmaceuticals, 18.","DOI":"10.3390\/ph18111730"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"De Masi, R., Orlando, S., and De Donno, A. (2021). The Age-Related Efficacy of Dimethyl Fumarate and Natalizumab in the Real-World Management of Multiple Sclerosis. Pharmaceuticals, 14.","DOI":"10.3390\/ph14020081"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Weideman, A.M., Tapia-Maltos, M.A., Johnson, K., Greenwood, M., and Bielekova, B. (2017). Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments. Front. Neurol., 8.","DOI":"10.3389\/fneur.2017.00577"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"54S","DOI":"10.1177\/1051228404266269","article-title":"Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis","volume":"14","author":"Rudick","year":"2004","journal-title":"J. Neuroimaging"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1212\/01.wnl.0000316810.01120.05","article-title":"Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis","volume":"71","author":"Zivadinov","year":"2008","journal-title":"Neurology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1212\/WNL.53.1.139","article-title":"A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)","volume":"53","author":"Simon","year":"1999","journal-title":"Neurology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/acn3.51302","article-title":"Dynamics of pseudo-atrophy in RRMS reveals predominant gray matter compartmentalization","volume":"8","author":"Giorgio","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Dwyer, M.G., Zivadinov, R., Tao, Y., Zhang, X., Kennedy, C., Bergsland, N., Ramasamy, D.P., Durfee, J., Hojnacki, D., and Weinstock-Guttman, B. (2015). Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: An open-label two-arm trial. BMC Neurol., 15.","DOI":"10.1186\/s12883-015-0488-9"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1177\/1352458512473190","article-title":"Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes","volume":"19","author":"Tur","year":"2013","journal-title":"Mult. Scler. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"17562864241303681","DOI":"10.1177\/17562864241303681","article-title":"A systematic literature review of the association between global brain atrophy and the Expanded Disability Status Scale score in people with multiple sclerosis","volume":"18","author":"Zivadinov","year":"2025","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/ana.25145","article-title":"Deep gray matter volume loss drives disability worsening in multiple sclerosis","volume":"83","author":"Eshaghi","year":"2018","journal-title":"Ann. Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"101476","DOI":"10.1016\/j.lanepe.2025.101476","article-title":"The effect of disease-modifying therapies on brain volume loss and disability accumulation in multiple sclerosis: A systematic review and network meta-analysis","volume":"59","author":"Cagol","year":"2025","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1212\/NXI.0000000000000616","article-title":"Contribution of normal aging to brain atrophy in MS","volume":"6","author":"Azevedo","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/jon.12625","article-title":"Aging and Brain Atrophy in Multiple Sclerosis","volume":"29","author":"Ghione","year":"2019","journal-title":"J. Neuroimaging"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1136\/jnnp.54.8.683","article-title":"Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: Concerted action guidelines","volume":"54","author":"Miller","year":"1991","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1212\/WNL.53.8.1698","article-title":"Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS","volume":"53","author":"Rudick","year":"1999","journal-title":"Neurology"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/6\/827\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T01:09:10Z","timestamp":1780535350000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/6\/827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["ph19060827"],"URL":"https:\/\/doi.org\/10.3390\/ph19060827","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]}}}